Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04386304 · ClinicalTrials.gov registry record · Phase 1
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
A Phase 1 study of Becker Muscular Dystrophy, sponsored by Epirium Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 3
- Study locations
NCT04386304: Completed Phase 1 study of Becker Muscular Dystrophy, sponsored by Epirium Bio.
NCT04386304 is a Phase 1 study of Becker Muscular Dystrophy that has completed, run by Epirium Bio. The registered enrollment target is 22 participants, below the 1,394-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04386304, a Phase 1 study of Becker Muscular Dystrophy, has completed, sponsored by Epirium Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 1, open-label, dose escalation study aimed at evaluating the safety, early efficacy and potential biomarkers of (+)-epicatechin in patients with Becker or Becker-like Muscular Dystrophy (BMD).
Primary Outcome
The TEAEs will be graded using the adult National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).
Conditions Studied
Interventions
- DRUG (+)-Epicatechin
Study Locations (3)
California
- UCLA Dept of Human Genetics - Los Angeles
- University of California - Davis Department of Physical Medicine and Rehabilitation - Sacramento
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2022-03-01 |
| Phase | Phase 1 |
What the finished NCT04386304 record still lists
NCT04386304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,394-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Becker Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which (+)-Epicatechin is the first listed.
NCT04386304 reports a single indexed study location in California, Missouri.
Frequently Asked Questions
What is clinical trial NCT04386304 about?
NCT04386304 is a clinical study titled "Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy". This is a Phase 1, open-label, dose escalation study aimed at evaluating the safety, early efficacy and potential biomarkers of (+)-epicatechin in patients with Becker or Becker-like Muscular Dystrophy (BMD).
What is the current status of trial NCT04386304?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-07-13. Estimated completion is 2022-03-01.
What conditions does trial NCT04386304 study?
This clinical trial studies the following conditions: Becker Muscular Dystrophy.
What interventions are being tested in trial NCT04386304?
The interventions under investigation include: (+)-Epicatechin (DRUG).
Who is sponsoring clinical trial NCT04386304?
This trial is sponsored by Epirium Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04386304 being conducted?
This trial has 3 study locations across California, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Becker Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04386304's enrollment target sits among peer trials
22 10th of 12 higher than 3 of 12 other Becker Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Becker Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sodium Nitrate to Improve Blood Flow
COMPLETED · Phase 1
-
Gentamicin Treatment of Muscular Dystrophy
COMPLETED · Phase 1
-
The Duchenne Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
RECRUITING
-
CureDuchenne Link®: A Resource for Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI